JPH0476971B2 - - Google Patents

Description

[Detailed description of the invention]

(Industrial Application Field) The present invention relates to an oral deodorant for body odor. The deodorant according to the present invention is orally administered to essentially suppress or eliminate various unpleasant body odors including bad breath and sweat odor. (Prior art) The elimination of unpleasant odors is extremely important from the perspective of not interfering with human communication, and also from the perspective of environmental conservation. BACKGROUND OF THE INVENTION Deodorants and deodorizing agents have been developed and put into practical use. For example, deodorants that target body odor, sweat odor, excrement odor, etc. of humans, pet animals, livestock, etc. include those that physically adsorb the target odor, and those that decompose odor components by contact. There are methods that use a separate aromatic substance to perform so-called "masking" so that the odor cannot be detected. On the other hand, deodorants that mainly target human halitosis include those that use aromatic substances such as chlorophyll, cinnamon, and diasmine as active ingredients, and those that suppress the activity of bacteria resident in the oral cavity that contribute to bad breath. There are some methods that use bactericidal drugs to suppress the disease. (Problems with the prior art) Among the deodorants of the prior art, those that are based on physical adsorption have problems in that they do not have immediate effect and have low deodorizing ability, and those that are based on decomposition. However, there are problems in that when applied, an unpleasant odor may be generated due to decomposition, and the effect is not sustainable. Therefore,
Generally, products based on masking are commonly used, but in this case, there is a strong tendency to choose a masking aromatic substance that has a strong scent, and if the scent is too strong, it is generally considered unpleasant. Fragrances are highly palatable, so even if some people think of them as fragrances, third parties often find them unpleasant, and they should be masked with the scent of masking aromatic substances. The problem is that when mixed with odor, it often produces an extremely unpleasant odor, even temporarily. Various types of deodorants have been proposed in the past, but all types not only have various problems, but also have negative effects. Most expected it. (Outline and Object of the Invention) By the way, the present inventors were conducting a nutritional experiment with phytic acids, and found that the oral administration of phytic acids gradually and essentially reduced the body odor of experimental animals, particularly bad breath, urine odor, and sweat odor. As a result of animal experiments, mainly on cats, which are known to have a strong urine odor, it was first confirmed that oral administration of phytic acids reduced urine odor. Gansho 63-19946 (Japanese Unexamined Patent Publication No. 1995-195860)]. Phytic acids are substances that are widely distributed in the plant world as mixed binding salts of calcium, magnesium, and even potassium, and rice bran contains 9.5-14.5% phytic acid. is the raw material for the production of phytic acid and its related substance myosinositol. This phytic acid and its salts are used for various purposes, and for medicinal purposes, for example, calcium phytate is used as a calcium reinforcing agent, rice bran itself and sodium phytate are used as an agent to prevent the recurrence of calcium stones, and calcium phytate is used as a preventive agent for calcium stones. It is used to treat hypercalcemia and reduce hypercalciuria in sarcoidosis patients.It is also used in general industry as a fermentation aid in the production of sake and wine, and it is also used as a fermentation aid in the production of sake and grape wine. It is used as a metal removal agent, and is further used as an antioxidant, anticorrosion agent, etc. Furthermore,
There have also been reports of deodorizing raw garlic by soaking it in a phytic acid solution (Japanese Patent Application Laid-Open No. 1983-1999).
259157). However, there have been no reports that oral administration of phytic acid or its salts to animals can reduce so-called unpleasant odors such as body odor (by the way, phytic acid itself is a strongly acidic substance, Also, its salts are odorless substances with a pH of 6-9). Therefore, the basic purpose of the present invention is to apply phytic acids as an oral deodorant for body odor, in view of the unique deodorizing action of phytic acids that was accidentally discovered in the course of the above-mentioned animal nutrition experiment. . A specific object of the present invention is to essentially reduce or eliminate the occurrence of unpleasant body odor by oral administration.
The objective is to provide a completely new type of oral body odor deodorant. (Means for Solving the Problems and Achieving the Objectives) According to the present invention, the problems in the prior art are:
This problem is solved by an oral body odor deodorant containing at least one substance selected from phytic acid and its salts as an active ingredient, and the above-mentioned specific objectives are achieved. In the present invention, phytate is naturally a non-toxic salt and means salts with metals, organic bases, basic amino acids, organic ester residues, etc. Specifically, for example, potassium phytate, phytate Mention may be made of sodium, arginine phytate, orthinine phytate, lysine phytate, histidine phytate, glucamine phytate, monoethanolamine phytate, diethanolamine phytate and triethanolamine phytate. There are various types of body odors that the oral deodorant of the present invention targets for deodorization, including general body odor, general halitosis, bad breath caused by garlic, alcohol, tobacco, etc., sweat odor (foot odor, (including armpit odor, etc.), senile odor, diseased fatty odor, menstrual odor, etc. In the production of the oral deodorant according to the present invention, phytic acid or its salt can be dissolved in water and used as a deodorant immediately, but it can also be powdered or granulated by adding excipients. It can also be formulated into granules, tablets, etc., and can also be made into dry syrup or syrup to make it easier to drink. Furthermore, since phytic acid is a strong acid and the body odor deodorant according to the present invention is administered orally, the PH
It is appropriate to prepare 6 to 8 kinds of salts and use these salts alone or in combination as an active ingredient. In this case, 1 mole of phytic acid has a pH of 6-8
The table below shows the number of moles of various bases required to make a salt of

[Table] (Dosage) The dosage when administered to humans varies depending on the symptoms (type and degree of odor), dosage form, etc., but is generally 1-500 phytic acid equivalent for adults.
mg/day is appropriate. (Examples, etc.) Next, the present invention will be described in further detail with reference to manufacturing examples and test examples. Production Example 1-11 (Torch Composition) The following various torch compositions were prepared. Torch composition A: A solution in which 294 g of sodium hydroxide was added to 660 g of phytic acid in terms of anhydride, and then the pH was adjusted to 6 by stirring while adding purified water. Torch composition B: A solution in which 412 g of potassium hydroxide was added to 660 g of phytic acid in terms of anhydride, and then the pH was adjusted to 6 by stirring while adding purified water. Torch composition C: A solution in which 177 g of lithium hydroxide was added to 660 g of phytic acid in terms of anhydride, and the pH was adjusted to 6 by stirring while adding purified water. Torch composition D: A solution in which 581 g of ethanolamine was added to 660 g of phytic acid in terms of anhydride, and then the pH was adjusted to 8 by stirring while adding purified water. Torch composition E: A solution in which 979 g of diethanolamine was added to 660 g of phytic acid in terms of anhydride, and then the pH was adjusted to 8 by stirring while adding purified water. Torch composition F: A solution in which 1805 g of triethanolamine was added to 660 g of phytic acid in terms of anhydride, and the pH was adjusted to 8 by stirring while adding purified water. Torch composition G: A solution in which 1657 g of N-methylglucamine was added to 660 g of phytic acid in terms of anhydride, and then the pH was adjusted to 7 by stirring while adding purified water. Torch composition H: A solution in which 1510 g of L-arginine was added to 660 g of phytic acid in terms of anhydride, and the pH was adjusted to 7 by stirring while adding purified water. Torch composition I: A solution in which 1753 g of L-lysine was added to 660 g of phytic acid in terms of anhydride, and the pH was adjusted to 6 by stirring while adding purified water. Torch composition J: A solution in which 1753 g of L-hisdine was added to 660 g of phytic acid in terms of anhydride, and the pH was adjusted to 6 by stirring while adding purified water. Torch composition K: 116 g of sodium hydroxide, 478 mg of potassium hydroxide, 6.08 g of calcium chloride (dihydrate) and 157 g of disodium hydrogen phosphate (anhydride) were added to 660 g of phytic acid in terms of anhydride, and then purified water was added. The pH of the solution was adjusted to 9 by stirring while adding. Production Examples 12-15 (Preparative Compositions) The following various pharmaceutical compositions were prepared. Formulation composition A: Torch composition K was collected (as phytic acid)
(contains 200mg), lactose is added to this and dried to make a total amount of 1000mg. Formulation composition B: Torch composition K was collected (as phytic acid)
(containing 100mg), lactose is added to this and dried to make a total amount of 1000mg. Formulation composition C: Torch composition K was collected (as phytic acid)
(contains 100mg), add purified water to the total amount.
Solution made to 1000mg. Pharmaceutical composition D: Torch composition K was collected (as phytic acid)
(contains 200mg), add purified water to the total amount.
Solution made to 1000mg. Production Example 16 (Elixir) A colorless and clear elixir was produced by mixing the various ingredients according to the following recipe to make a homogeneous mixture. The single dose of this drug is 5 ml and contains 50 mg of phytic acid. Pharmaceutical Composition C 100 (g) Pharmacopoeia Orange Sei 24 (ml) Ethanol 400 Glycerin 400 Remaining amount of purified water 1000 (ml) Manufacturing Example 17 (Capsules) Fill into 2-mesh capsules using the following formula and using the usual method. Capsules (40% phytic acid per capsule)
mg) was produced. Pharmaceutical composition A 200 (mg) Lactose 20 Corn starch 38 Magnesium stearate 2 total 260 mg/unit Production example 18 (granules) Granules (granules) were prepared by wet granulation using the following formulation and water and ethanol. (containing 120 mg of phytic acid per package). Pharmaceutical composition A 600 (mg) Lactose 140 Corn starch 250 Hydroxypropyl cellulose 10 total 1000 mg/packet Production Example 19 (Powder) Pharmaceutical composition A was packaged into 1.5 g portions using aluminum heat seal packaging. This product contains 300mg of phytic acid per package. Production Example 20 (Tablets) Tablets with a diameter of 7 mm (each tablet contains 20 mg of phytic acid) were produced by compression molding according to the following formulation and by a conventional method. Pharmaceutical Composition A 100 (mg) Corn starch 19 Crystalline cellulose 30 Magnesium stearate 1 total 150 mg/tablet manufacturing example 21 (Syrup) A colorless and clear syrup was manufactured by dissolving and mixing various ingredients according to the following formulation. . The single dose of this drug is 20ml, and it contains 100mg of phytic acid. Pharmaceutical composition C 50 (g) White sugar 300 D-sorbitol (70%) 250 Methyl p-oxybenzoate 0.3 Propyl p-oxybenzoate 0.15 Sodium citrate 10 Citric acid 1.5 Flavor 2 Total amount of purified water remaining 1000 ( ml) Production Example 22 (Dry Syrup) A dry syrup was produced by collecting and mixing various ingredients according to the following formulation and wet granulating them using water and ethanol. The single dose of this dry syrup is 1 g, and each packet contains 10 mg of phytic acid. Pharmaceutical composition B 100 (mg) Sodium citrate 2.4 Anhydrous citric acid 2.2 Tragacanth powder 2.7 White sugar Appropriate amount Hydroxypropyl cellulose 3.0 Flavor trace meter 1000 mg/bag manufacturing example 23 (lozenge) First, prepare the pharmaceutical composition in the following proportions. Product A and white sugar are collected and mixed, and this mixture is wet granulated with water and ethanol, and dried at 35°C or lower. Lactose and magnesium stearate were added and mixed to this dried product, and then tableted to produce a lozenge with a diameter of 15 mm (each tablet weighed 1 g and contained 20 mg of phytic acid). Pharmaceutical Composition A 100 (mg) White Sugar 870 Lactose 20 Magnesium Stearate 10 Total 1000 mg/Tablet Manufacturing Example 24 (Limonade Agent) A limonade agent was manufactured according to the following formulation and in a conventional manner. The single dose of this drug is 30ml, and it contains 300mg of phytic acid. Pharmaceutical Composition C 3 (g) Simple Syrup 2.5 Purified Water Remaining Total 30 ml/time Production Example 25 (Drink) A clear and colorless drink (oral liquid) was produced according to the following recipe and in a conventional manner. The single dose of this drug is 30ml, which contains 100mg of phytic acid. Pharmaceutical composition C 1.0 (g) Honey 0.5 White Sugar 2.0 Citric acid Appropriate amount Sodium citrate Appropriate amount Peppermint Trace amount of purified water remaining Total 30 ml/time Production example 26 (limonade agent) Limonade agent was manufactured according to the following recipe and in a conventional manner. . The single dose of this drug is 20ml, and it contains 100mg of phytic acid. Phytic acid 0.50 (g) Simple syrup 10.0 Total amount of purified water remaining 100 (ml) Test example 1 (stability test) For each formulation of manufacture 16-26, glass bottles, polyethylene terephthalate containers, aluminum foil bags, etc. The phytic acid content was measured at the start of the test and after 3 weeks of storage at 60°C, and no decrease was observed in the phytic acid content even after storage, indicating that each formulation has excellent stability. There was found. Test Example 2 (deodorization of bad breath) A Test method A group of 3 healthy people were made to ingest the following malodor-producing substances, and immediately after that, a potassium phytate aqueous solution (105 mg/10 ml) was administered to the test group. However, the control group was given an equal amount of water only, and a breath odor test was conducted by three third-party inspectors (it was judged as positive if two or more of the three people could smell the odor), and a sensitivity test was conducted based on self-report. Implement over time. Offensive substances (a) Garlic (10g raw) (b) Chives (50g cooked) (c) Ratsukiyo (50g pickles) (d) Onions (100g processed) (e) Scallions (cooked) (100g) (f) Tobacco (sensitivity test conducted by a third party on people who smoke 50 or more cigarettes a day) (g) Alcohol (drink 300ml of sake on an empty stomach) (B) Test results Third party test In a sensitivity test conducted by a group of researchers, all testers in the control group tested positive at 1, 3, 6, 12, and 24 hours after ingestion, whereas in the drug-administered test group, The inspector determined that the halitosis was already mild during the first test one hour after ingestion, and that there was a clear reduction in halitosis during the second test three hours later. Similar results were also observed in the self-reported results, and while some subjects in the control group complained of nausea, a sense of strange smell, and an abnormal sense of smell, no subjects in the test group complained of any abnormality. Test Example 3 (deodorization of sweat odor) The capsule preparation of Production Example 17 was given to volunteers with hyperhidrotic dysodor syndrome (3 people each with foot odor and armpit odor), and one capsule was orally administered after each meal. (120 mg/day as phytic acid) was administered continuously for one week, a sensitivity test was conducted by three third-party inspectors, and the degree of improvement was investigated by self-reporting. All examiners responded that their symptoms improved over time, and the self-reported results were similar. (Effects of the Invention) The body odor deodorant according to the present invention can essentially reduce or eliminate general body odor, bad breath, sweat odor, etc. of animals including humans. Phytic acid and its salts, which are the active ingredients of the body odor deodorant according to the present invention, are odorless and can be administered orally, and can be in either liquid or solid form, so they can be ingested. It's easy. In addition, body odor deodorants can be used in the form of food and beverages and luxury items such as seasonings, and are extremely easy to use continuously over a long period of time, and therefore have a long-lasting effect. can. This is extremely advantageous. This is because when applied to humans, especially long-term care patients who are unable to clean themselves or the bedridden elderly, etc., there are many cases in which a strange odor is generated. This is because body odor can be reduced by ingesting the drug in the form of a luxury item or a luxury item, thereby significantly reducing the discomfort felt by nurses and the like.

Claims (1)

[Scope of Claims] 1. An oral deodorant for body odor, characterized by containing as an active ingredient at least one substance selected from phytic acid and its salts. 2. The oral deodorant according to claim 1, wherein the body odor is bad breath, sweat odor, fat odor, old man odor, or menstrual odor.